MedPath

Safety and efficacy of conditioning regimen with once-daily intravenous busulfan and fludarabine or cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myelogenous leukemia or myelodysplastic syndrome

Not Applicable
Recruiting
Conditions
acute myelogenous leukemia, myelodysplastic syndrome
Registration Number
JPRN-UMIN000015647
Lead Sponsor
Second Department of Internal Medicine, Shinshu University of School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

patients with antibody of HIV patients has other malignancies patients has uncontrollable psychiatric disorders patients has active infections patients has history of hematopoietic stem cell transplantation patients has allergy of the drugs that use in protocol pregnant woman

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
event-free survival at day 100 from transplantation
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath